AI-based Antibody Therapeutics Developability Assessment and Its Engineering
Monoclonal antibodies (mAbs) have become essential in treating a wide spectrum of diseases,
with over 100 therapeutic antibody products now approved and commercially available. Although mAbs represent
the fastest-growing sector in therapeutics, their development is complex, with developability being a
crucial consideration. Developability evaluates the potential of an antibody candidate to be produced as a
safe and effective drug.
In the context of Contract Research and Manufacturing Organizations (CRMOs), the
developability assessment focuses on ensuring that an antibody candidate can progress through the chemistry,
manufacturing, and control (CMC) processes efficiently, affordably, and within an acceptable timeframe. It’s
important to examine and refine the properties related to developability early on, ideally during the
discovery phase, to reduce the chances of advancing an antibody with limited developability to the CMC
stage. Artificial intelligence is transforming bioinformatics research and its applications, particularly in
protein and antibody analysis. AI methods are now being employed to improve the developability screening and
optimization of antibody candidates.
In this webinar, we are excited to present our Immunoinformatics Comprehensive Service
Platform, which leverages AI for the developability assessment of antibody therapeutics. This covers
assessments of immunogenicity, viscosity, aggregation, degradation, and post-translational modifications
(PTMs). We will also cover our antibody engineering services, including humanization, caninization,
felinization, and optimizing expression. Case studies will be presented to demonstrate our capabilities in
assessing developability and performing antibody engineering. The webinar will end with a Q&A session,
allowing participants to delve into any specific areas of interest regarding AI in antibody development.
Join us to learn how our AI-based platform can facilitate the development process for
antibody therapeutics, ensuring candidates are not only therapeutically effective but also viable for
large-scale production and clinical use.
이 웨비나에서는 항체 치료제의 개발 가능성 평가를 위한 AI 기반 면역정보학 종합 서비스 플랫폼을 소개합니다. 이 플랫폼은 면역원성, 점도, 응집, 분해, 번역 후 변형(PTMs) 평가를
포함합니다. 또한 항체 인간화, 개화, 고양이화, 발현 최적화를 포함한 항체 엔지니어링 서비스도 제공합니다. 사례 연구를 통해 개발 가능성 평가와 항체 엔지니어링 능력을 시연할 예정입니다.
웨비나는 Q&A 세션으로 마무리되어, 항체 개발에 있어 AI의 특정 분야에 대한 참가자들의 질문에 답변할 기회를 제공합니다.
이 웨비나에 참여하여 AI 기반 플랫폼이 어떻게 항체 치료제 개발 과정을 촉진하고, 후보 물질이 치료적으로 효과적일 뿐만 아니라 대규모 생산 및 임상 사용에도
적합하게 만들 수 있는지 알아보세요.
Most Popular Products
CRISPR Gene Editing
Antibodies
Protein Electrophoresis and Blotting
Molecular Biology
Stable Cell Lines
Cell Therapy
Diagnostics
Resources
Dr. Carter Hao
